Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes

Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J H Brown, Caihong Zhou, Jiejie Deng, Ming Wei Wang

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a twodomain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable nonpeptidicGLP-1R agonists have been hampered, small-moleculemodulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

Original languageEnglish (US)
Pages (from-to)954-1013
Number of pages60
JournalPharmacological Reviews
Volume68
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Glucagon-Like Peptide 1
G-Protein-Coupled Receptors
Ligands
Enteroendocrine Cells
Pharmacology
Peptides
Peptide Hormones
Therapeutics
Type 2 Diabetes Mellitus
Biological Availability
Intestines
Pancreas
Stomach
Homeostasis
Central Nervous System
Obesity
Eating
Glucose

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

de Graaf, C., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., ... Wang, M. W. (2016). Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes. Pharmacological Reviews, 68(4), 954-1013. https://doi.org/10.1124/pr.115.011395

Glucagon-like peptide-1 and its class B G protein-coupled receptors : A long march to therapeutic successes. / de Graaf, Chris; Donnelly, Dan; Wootten, Denise; Lau, Jesper; Sexton, Patrick M.; Miller, Laurence J.; Ahn, Jung Mo; Liao, Jiayu; Fletcher, Madeleine M.; Yang, Dehua; Brown, Alastair J H; Zhou, Caihong; Deng, Jiejie; Wang, Ming Wei.

In: Pharmacological Reviews, Vol. 68, No. 4, 01.10.2016, p. 954-1013.

Research output: Contribution to journalArticle

de Graaf, C, Donnelly, D, Wootten, D, Lau, J, Sexton, PM, Miller, LJ, Ahn, JM, Liao, J, Fletcher, MM, Yang, D, Brown, AJH, Zhou, C, Deng, J & Wang, MW 2016, 'Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes', Pharmacological Reviews, vol. 68, no. 4, pp. 954-1013. https://doi.org/10.1124/pr.115.011395
de Graaf, Chris ; Donnelly, Dan ; Wootten, Denise ; Lau, Jesper ; Sexton, Patrick M. ; Miller, Laurence J. ; Ahn, Jung Mo ; Liao, Jiayu ; Fletcher, Madeleine M. ; Yang, Dehua ; Brown, Alastair J H ; Zhou, Caihong ; Deng, Jiejie ; Wang, Ming Wei. / Glucagon-like peptide-1 and its class B G protein-coupled receptors : A long march to therapeutic successes. In: Pharmacological Reviews. 2016 ; Vol. 68, No. 4. pp. 954-1013.
@article{dbdc23fbb3af41c98827d98fc377b160,
title = "Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes",
abstract = "Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a twodomain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable nonpeptidicGLP-1R agonists have been hampered, small-moleculemodulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.",
author = "{de Graaf}, Chris and Dan Donnelly and Denise Wootten and Jesper Lau and Sexton, {Patrick M.} and Miller, {Laurence J.} and Ahn, {Jung Mo} and Jiayu Liao and Fletcher, {Madeleine M.} and Dehua Yang and Brown, {Alastair J H} and Caihong Zhou and Jiejie Deng and Wang, {Ming Wei}",
year = "2016",
month = "10",
day = "1",
doi = "10.1124/pr.115.011395",
language = "English (US)",
volume = "68",
pages = "954--1013",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Glucagon-like peptide-1 and its class B G protein-coupled receptors

T2 - A long march to therapeutic successes

AU - de Graaf, Chris

AU - Donnelly, Dan

AU - Wootten, Denise

AU - Lau, Jesper

AU - Sexton, Patrick M.

AU - Miller, Laurence J.

AU - Ahn, Jung Mo

AU - Liao, Jiayu

AU - Fletcher, Madeleine M.

AU - Yang, Dehua

AU - Brown, Alastair J H

AU - Zhou, Caihong

AU - Deng, Jiejie

AU - Wang, Ming Wei

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a twodomain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable nonpeptidicGLP-1R agonists have been hampered, small-moleculemodulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

AB - Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a twodomain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable nonpeptidicGLP-1R agonists have been hampered, small-moleculemodulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=84988028207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988028207&partnerID=8YFLogxK

U2 - 10.1124/pr.115.011395

DO - 10.1124/pr.115.011395

M3 - Article

C2 - 27630114

AN - SCOPUS:84988028207

VL - 68

SP - 954

EP - 1013

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 4

ER -